Abbott Laboratories (ABT)
NYSE: ABT ¡ Real-Time Price ¡ USD
103.00
-0.87 (-0.84%)
Nov 20, 2026, 4:00 PM EST - Market closed
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $13.01B in the quarter ending September 30, 2026, with 14.46% growth. This brings the company's total for the last twelve months to $48.23B, up 10.00% year-over-year. In the year 2025, Abbott Laboratories had annual revenue of $44.33B with 5.67% growth. That makes Abbott Laboratories the 271st largest company in the world by revenue and 102nd in the United States.
Revenue (ttm)
$48.23B
Revenue Growth
+10.00%
P/S Ratio
3.70
Revenue / Employee
$419,383
Employees
115,000
Market Cap
178.39B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Abbott Laboratories breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.33B | 2.38B | 5.67% |
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | 31.90B | 1.33B | 4.34% |
| Dec 31, 2018 | 30.58B | 3.19B | 11.64% |
| Dec 31, 2017 | 27.39B | 6.54B | 31.35% |
| Dec 31, 2016 | 20.85B | 448.00M | 2.20% |
| Dec 31, 2015 | 20.41B | 158.00M | 0.78% |
| Dec 31, 2014 | 20.25B | 590.00M | 3.00% |
| Dec 31, 2013 | 19.66B | 607.00M | 3.19% |
| Dec 31, 2012 | 19.05B | -2.36B | -11.01% |
| Dec 31, 2011 | 21.41B | -13.76B | -39.13% |
| Dec 31, 2010 | 35.17B | 4.40B | 14.31% |
| Dec 31, 2009 | 30.76B | 1.24B | 4.19% |
| Dec 31, 2008 | 29.53B | 3.61B | 13.94% |
| Dec 31, 2007 | 25.91B | 3.44B | 15.30% |
| Dec 31, 2006 | 22.48B | 138.51M | 0.62% |
| Dec 31, 2005 | 22.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medtronic | 37.54B |
| Stryker | 26.30B |
| GE HealthCare Technologies | 21.64B |
| Boston Scientific | 21.07B |
| Koninklijke Philips | 20.16B |
| Zimmer Biomet Holdings | 8.57B |
| Edwards Lifesciences | 6.67B |
| STERIS | 6.17B |
ABT News
- 2 days ago - Abbott begins clinical trial for investigational Encantor system - TheFly
- 2 days ago - Abbott initiates VOYAGER clinical trial for investigational Encantor⢠software-guided balloon-expandable TAVI system to treat aortic stenosis - PRNewsWire
- 2 days ago - Leerink upgrades Abbott to Outperform, raises target to $124 - TheFly
- 2 days ago - Abbott upgraded to Outperform from Market Perform at Leerink - TheFly
- 12 days ago - Abbott price target raised to $125 from $115 at BofA - TheFly
- 17 days ago - These 12 stocks are good bets to beat the 10-year Treasury over the next decade - Market Watch
- 19 days ago - Abbottâs Amulet 360 device shows efficacy in stroke incidence reduction - TheFly
- 19 days ago - Late-breaking one-year data show Abbott's next-generation Amulet 360⢠device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke - PRNewsWire